Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q2 2016 · 10-Q
Revenue$2.11M$2.11M+44.7% vs Q2 2015 Net Income-$2.51M-$2.51MN/M vs Q2 2015 EPS Diluted-$5.88-$5.88N/M vs Q2 2015 Operating Income-$2,484,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$2,008,000N/M Margins · derivedOperating margin-117.8%+53.1 pt vs Q2 2015
Net margin-118.9%+57.0 pt vs Q2 2015
ended Jun 30, 2016 · filed Aug 15, 2016 · 46 d after period end